| James Edward Cureington, RNP | |
|
555 W 6th St, Mountain Home, AR 72653-3409 | |
| (870) 425-8288 | |
| (870) 425-8299 |
| Full Name | James Edward Cureington |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Location | 555 W 6th St, Mountain Home, Arkansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063414126 | NPI | - | NPPES |
| 5W110 | Other | AR | AR BCBS # |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | P01779 (Arkansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| James Edward Cureington, RNP 555 W 6th St, Mountain Home, AR 72653-3409 Ph: (870) 425-8288 | James Edward Cureington, RNP 555 W 6th St, Mountain Home, AR 72653-3409 Ph: (870) 425-8288 |
News Archive
Heart failure patients are more likely to comply with important non-medication interventions, such as fluid and salt restrictions and regular weighing, when they have intensive support from a heart failure nurse and multidisciplinary team than if they do not, researchers reported at the American Heart Association's Scientific Sessions 2007.
Avecia Biotechnology, Inc., a leading provider of drug development and manufacturing services for oligonucleotide therapeutics, has reached agreement with Pfizer Inc. regarding the commercial supply of a key component of Macugen (pegaptanib sodium injection), marketed in the E.U. by Pfizer for the treatment of wet Age-Related Macular Degeneration.
A standardized care pathway for children with adolescent idiopathic scoliosis undergoing spinal fusion surgery reduces the need for opioid pain medications and shortens hospital stays at Children's National Health System.
Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 2a clinical trial that will evaluate multiple combinations of VX-770 and VX-809, investigational oral cystic fibrosis transmembrane conductance regulator (CFTR) modulators for the treatment of cystic fibrosis (CF). The trial is designed to evaluate the safety and tolerability of VX-809 dosed alone for 14 days followed by dosing of VX-809 in combination with VX-770 for 7 days.
› Verified 8 days ago
Adrienne Renee Mccutcheon, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1301 Highway 62 E, Mountain Home, AR 72653 Phone: 870-970-7140 Fax: 870-701-3181 | |
Jodi Nicole Bodenhamer, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 622 Broadmoor Dr, Mountain Home, AR 72653 Phone: 870-508-1765 Fax: 870-508-1679 | |
Ms. Corinne Hiser, ANP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 630 Burnett Dr, Mountain Home, AR 72653 Phone: 870-425-6971 Fax: 870-508-8900 | |
Caleb Michael Lunday, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1301 Highway 62 E, Mountain Home, AR 72653 Phone: 870-970-7140 Fax: 870-701-3181 | |
Jennifer Lambert, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 65 Wal Mart Dr, Mountain Home, AR 72653 Phone: 870-492-2200 Fax: 870-492-2264 | |
Meagan Thitoff, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 624 Hospital Dr, Mountain Home, AR 72653 Phone: 870-508-1000 |